Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies

Summary

Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation.

It was our objective to test whether the risk of thrombosis increases with: 1) increasing titres of anticardiolipin antibodies (aCL) after adjustment for other cardiovascular risk factors and 2) the number of aPL detected.

In a cross-sectional study, blood was collected from clinics in two teaching hospitals. The study included 208 individuals suspected of having an aPL and 208 age- and sex-matched controls having blood drawn for a complete blood count.

Clinical variables included history of previous arterial (ATE) or venous (VTE) thrombotic events, traditional risk factors for cardiovascular disease, and systemic lupus erythematosus (SLE). Laboratory variables included IgG/IgM aCL, lupus anticoagulant, and IgG/IgM anti-β2-glycoprotein I.

Mean age was 46.5 years and 83% were female. Seventy-five of the 416 participants had > 1 aPL, and 69 had confirmed > 1 ATE or VTE. Family history was positive in 48% of participants, smoking in 28%, hypertension in 16%, diabetes in 6%, and SLE in 20%. A 10-unit increase in aCL IgG titre was associated with an odds ratio (OR) [95% CI] of 1.07 [1.01-1.13] for ATE and 1.06 [1.02 - 1.11] for VTE. The odds of a previous thrombosis increased with each additional aPL detected: 1.5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE.

These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event.

Keywords

Antiphospholipid syndrome - antiphospholipid antibodies - anti-cardiolipin antibody - thrombosis

• References

• 1 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
• 2 Lockshin MD, Sammaritano LR, Schwartz-man S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-3.
• 3 Levine JS, Branch DW, Rauch J. The anti-phospholipid syndrome. N Engl J Med 2002; 346: 752-63.
• 4 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9.
• 5 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-28.
• 6 Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanola-mine in the presence of prothrombin. Thromb Haemost 1998; 80: 936-41.
• 7 Price BE, Rauch J, Shia MA. et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-8.
• 8 SAS Institute Inc The SAS System for Windows. (8.2). 2002. Cary, North Carolina: The SAS Institute;
• 9 el Roeiy A, Gleicher N. Definition of normal autoantibody levels in an apparently healthy population. Obstet Gynecol 1988; 72: 596-602.
• 10 Briley DP, Coull BM, Goodnight SH. jr Neurological disease associated with antiphospho-lipid antibodies. Ann Neurol 1989; 25: 221-7.
• 11 Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623-5.
• 12 Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231-6.
• 13 Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischaemic heart disease: marker or myth?. Br Heart J 1993; 69: 391-4.
• 14 Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 1998; 21: 4-11.
• 15 Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159-63.
• 16 Levine SR, Salowich-Palm L. et al. IgG anti-cardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28: 1660-5.
• 17 Vaarala O, Manttari M, Manninen V. et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
• 18 Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol 1999; 83: 1490-4. A8.
• 19 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
• 20 Zuckerman E, Toubi E, Shiran A. et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am J Med 1996; 101: 381-6.
• 21 Kenet G, Sadetzki S, Murad H. et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
• 22 Salomon O, Steinberg DM, Zivelin A. et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-8.
• 23 Pablos JL, Caliz RA, Carreira PE. et al. Risk of thrombosis in patients with antiphospholip-id antibodies and factor V Leiden mutation. J Rheumatol 1999; 26: 588-90.
• 24 Galli M, Finazzi G, Duca F, Norbis F, Moia M. The G1691→A mutation of factor V, but not the G20210→A mutation of factor II or the C677→T mutation of methylenetetrahydrof-olate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000; 108: 865-70.
• 25 Nojima J, Suehisa E, Akita N. et al. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997; 96: 447-50.
• 26 Gattorno M, Buoncompagni A, Molinari AC. et al. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the anti-phospholipid syndrome. Br J Rheumatol 1995; 34: 873-81.
• 27 Ginsberg JS, Wells PS, Brill-Edwards P. et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
• 28 Horbach DA, van Oort E, Donders RC, Derk-sen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
• 29 Anticardiolipin antibodies are an independent risk factor for first ischemic stroke The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993; 43: 2069-73.
• 30 Wahl DG, De Maistre E, Guillemin F, Regnault V, Perret-Guillaume C, Lecompte T. Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. QJM 1998; 91: 125-30.
• 31 Gomez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcon-Segovia D. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999; 106: 417-23.
• 32 McNally T, Mackie IJ, Machin SJ, Isenberg DA. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995; 34: 1031-6.
• 33 Fiallo P, Tomasina C, Clapasson A, Cardo PP. Antibodies to beta(2)-glycoprotein I in ischemic stroke. Cerebrovasc Dis 2000; 10: 293-7.
• 34 Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S. et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466-74.
• 35 Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997; 78: 1008-14.
• 36 Cucurull E, Espinoza LR, Mendez E. et al. Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 1999; 8: 134-41.
• 37 Zanon E, Prandoni P, Vianello F, Saggiorato G, Carraro G, Bagatella P. et al. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res 1999; 96: 269-74.
• 38 Palosuo T, Virtamo J, Haukka J. et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men—a nested case-control study. Thromb Haemost 1997; 78: 1178-82.
• 39 Vaarala O, Puurunen M, Manttari M, Man-ninen V, Aho K, Palosuo T. Antibodies to pro-thrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-9.
• 40 Cuadrado MJ, Tinahones F, Camps MT. et al. Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. QJM 1998; 91: 619-26.